Bank of America Corp DE Raises Holdings in Sensei Biotherapeutics, Inc. $FTH

Key Points

• Bank of America significantly increased its Sensei Biotherapeutics stake by 10,692.5% in the first quarter, reaching 33,025 shares valued at approximately $1.04 million. Institutional investors collectively own 10.5% of the company.
• Company insiders have also been buying shares, with executives purchasing 49,494 shares worth roughly $1.19 million over the past 90 days.
• Sensei’s shares opened at $40.05, near their 52-week high, while analysts maintain a “Moderate Buy” consensus with an average price target of $55. The company also beat quarterly earnings expectations, reporting a loss of $2.84 per share versus the expected $5.04 loss.

Bank of America Corp DE lifted its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Free Report) by 10,692.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,025 shares of the company's stock after buying an additional 32,719 shares during the quarter. Bank of America Corp DE owned approximately 2.46% of Sensei Biotherapeutics worth $1,041,000 at the end of the most recent quarter.

Separately, Renaissance Technologies LLC lifted its stake in Sensei Biotherapeutics by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company's stock worth $123,000 after acquiring an additional 1,100 shares during the period. Institutional investors and hedge funds own 10.50% of the company's stock.

Insiders Place Their Bets

In other news, CEO Anand Kiran Parikh purchased 2,806 shares of the stock in a transaction on Monday, June 22nd. The stock was bought at an average price of $19.76 per share, with a total value of $55,446.56. Following the transaction, the chief executive officer owned 764,234 shares in the company, valued at $15,101,263.84. The trade was a 0.37% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brian C. Stephenson purchased 9,391 shares of the stock in a transaction on Wednesday, June 24th. The shares were purchased at an average cost of $26.13 per share, with a total value of $245,386.83. Following the transaction, the chief financial officer owned 26,804 shares in the company, valued at $700,388.52. This trade represents a 53.93% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 49,494 shares of company stock valued at $1,188,822 in the last 90 days. 7.00% of the stock is currently owned by company insiders.

Sensei Biotherapeutics Trading Up 2.7%

FTH opened at $40.05 on Friday. The firm has a market capitalization of $1.03 billion, a P/E ratio of -0.28 and a beta of -0.28. The firm's 50-day moving average is $29.86. Sensei Biotherapeutics, Inc. has a 52-week low of $7.45 and a 52-week high of $41.16.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping the consensus estimate of ($5.04) by $2.20. On average, research analysts expect that Sensei Biotherapeutics, Inc. will post -13.18 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

FTH has been the topic of a number of research reports. Raymond James Financial started coverage on shares of Sensei Biotherapeutics in a research report on Friday, July 31st. They set an "outperform" rating and a $56.00 target price on the stock. Wall Street Zen upgraded shares of Sensei Biotherapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 22nd. Oppenheimer started coverage on shares of Sensei Biotherapeutics in a report on Tuesday, July 28th. They set an "outperform" rating and a $60.00 price objective on the stock. Loop Capital set a $50.00 price objective on shares of Sensei Biotherapeutics in a research note on Thursday, May 28th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $55.00.

Sensei Biotherapeutics Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.